Amitriptyline for fibromyalgia: Off-label treatment, but non-inferior to approved medication
Int J Rheum Dis
.
2023 Apr;26(4):607-608.
doi: 10.1111/1756-185X.14618.
Authors
Cheng Hsien Hung
1
,
Yung-Heng Lee
2
3
4
5
,
James Cheng-Chung Wei
6
7
8
9
Affiliations
1
Department of Pharmacy, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan.
2
Department of Orthopedics, Cishan Hospital, Ministry of Health and Welfare, Kaohsiung, Taiwan.
3
Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung, Taiwan.
4
Department of Senior Services Industry Management, Minghsin University of Science and Technology, Hsinchu, Taiwan.
5
Department of Recreation and Sport Management, Shu-Te University, Kaohsiung, Taiwan.
6
Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
7
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
8
Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
9
Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
PMID:
37002904
DOI:
10.1111/1756-185X.14618
No abstract available
Publication types
Editorial
Comment
MeSH terms
Amitriptyline* / adverse effects
Fibromyalgia* / diagnosis
Fibromyalgia* / drug therapy
Humans
Off-Label Use
Substances
Amitriptyline